Purpose: This study aimed to compare
the survival benefits between different total radiation doses in definitive
chemoradiotherapy (dCRT) for inoperable esophageal carcinoma (EC) based on
modern radiotherapy techniques. Methods: A systematic review was
performed by searching the databases of PubMed, EMBASE, Cochrane Central
Register of Controlled Trials and Web of Science. All studies published prior
to November 30, 2022, comparing radiation dose and disease-related outcomes in EC patients. The
hazard ratio (HR) and odds ratio (OR) were used to describe the risk of
outcomes and toxicities. Results: Seven prospective trials involving
1124EC patients were enrolled for analyses. The results revealed that the
effect on overall survival (HR = 0.99, 95% CI = 0.85 - 1.16, P = 0.94), local progression-free survival (HR
= 0.83, 95% CI = 0.58 - 1.17, P =
0.29), local regional progression-free survival(HR = 0.94, 95% CI = 0.76 - 1.17, P = 0.61), progression-free survival (HR =
0.90, 95% CI = 0.71 - 1.13, P =
0.35) was similar in the high-dose and standard-dose groups. Additionally, a
high radiation dose exhibited a potential
disadvantage in respiratory toxicities when compared with a standard dose (4.8%
vs 2.2%, OR 2.11, P=0.06). Conclusions: The efficacy of the HD
group (≥60Gy) and
the SD group (approximately 50 Gy) for inoperable local advanced EC was
similar. However, the HD group exhibited a high radiation dose exhibited a potential
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
Minsky, B.D., Pajak, T.F., Ginsberg, R.J., Pisansky, T.M., Martenson, J., Komaki, R., et al. (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose versus Standard-Dose Radiation Therapy. Journal of Clinical Oncology, 20, 1167-1174.
https://doi.org/10.1200/JCO.2002.20.5.1167
[3]
Cooper, J.S., Guo, M.D., Herskovic, A., Macdonald, J.S., Martenson, J.A., Al-Sarraf, M., et al. (1999) Chemoradiotherapy of Locally Advanced Esophageal Cancer: long-Term Follow-up of a Prospective Randomized Trial (RTOG 85-01). JAMA, 281, 1623-1627. https://doi.org/10.1001/jama.281.17.1623
[4]
Tahmeed, T., Tibdewal, A., Ghosh-Laskar, S., Mummudi, N., Noronha, V., Prabhash, K., et al. (2021) Patterns of Failure and Adequacy of Clinical Target Volume (CTV) Margins in Patients Treated with Definitive Chemo-Radiation in Esophageal Cancer. Diseases of the Esophagus, 34, Article ID: Doab052.782.
https://doi.org/10.1093/dote/doab052.782
[5]
Crosby, T., Hurt, C.N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., et al. (2013) Chemoradiotherapy with or without Cetuximab in Patients with Oesophageal Cancer (SCOPE1): A Multicentre, Phase 2/3 Randomised Trial. The Lancet Oncology, 14, 627-637. https://doi.org/10.1016/S1470-2045(13)70136-0
[6]
Welsh, J., Settle, S.H., Amini, A., Xiao, L., Suzuki, A., Hayashi, Y., et al. (2012) Failure Patterns in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Cancer, 118, 2632-2640. https://doi.org/10.1002/cncr.26586
[7]
Chang, C.-L., Tsai, H.-C., Lin, W.-C., Chang, J.-H., Hsu, H.-L., Chow, J.-M., et al. (2017) Dose Escalation Intensity-Modulated Radiotherapy-Based Concurrent Chemoradiotherapy Is Effective for Advanced-Stage Thoracic Esophageal Squamous Cell Carcinoma. Radiotherapy and Oncology, 125, 73-79.
https://doi.org/10.1016/j.radonc.2017.08.025
[8]
Chen, C.-Y., Li, C.-C. and Chien, C.-R. (2016) Does Higher Radiation Dose Lead to Better Outcome for Non-Operated Localized Esophageal Squamous Cell Carcinoma Patients Who Received Concurrent Chemoradiotherapy? A Population Based Propensity-Score Matched Analysis. Radiotherapy and Oncology, 120, 136-139.
https://doi.org/10.1016/j.radonc.2016.04.042
[9]
He, L., Allen, P.K., Potter, A., Wang, J., Chang, J.Y., Gomez, D.R., et al. (2014) Re-Evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 9, 1398-1405.
https://doi.org/10.1097/JTO.0000000000000267
[10]
Taher, A.N., Elawady, R.A. and Amin, A. (2109) Dosimetric Comparison between Three Dimensional Conformal Radiation Therapy (3DCRT) & Intensity Modulated Radiation Therapy (IMRT) in Mid-Lower Oesophageal Carcinoma. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 8, 121-129. https://doi.org/10.4236/ijmpcero.2019.82011
[11]
Xiao, L., Czito, B.G., Pang, Q., Hui, Z., Jing, S., Shan, B., et al. (2020) Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. Journal of Cancer, 11, 4605-4613. https://doi.org/10.7150/jca.44447
[12]
Kim, H.J., Suh, Y.-G., Lee, Y.C., Lee, S.K., Shin, S.K., Cho, B.C., et al. (2017) Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Research and Treatment, 49, 669-677.
https://doi.org/10.4143/crt.2016.354
[13]
Zhang, Z., Liao, Z., Jin, J., Ajani, J., Chang, J.Y., Jeter, M., et al. (2005) Dose-Response Relationship in Locoregional Control for Patients with Stage II-III Esophageal Cancer Treated with Concurrent Chemotherapy and Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 61, 656-664.
https://doi.org/10.1016/j.ijrobp.2004.06.022
[14]
Luo, H.-S., Huang, H.-C. and Lin, L.-X. (209) Effect of Modern High-Dose versus Standard-Dose Radiation in Definitive Concurrent Chemo-Radiotherapy on Outcome of Esophageal Squamous Cell Cancer: A Meta-Analysis. Radiation Oncology, 14, Article No. 178. https://doi.org/10.1186/s13014-019-1386-x
[15]
Sun, X., Wang, L., Wang, Y., Kang, J., Jiang, W., Men, Y., et al. (2020) High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma with Modern Radiotherapy Techniques: A Meta-Analysis. Frontiers in Oncology, 10, Article 1222. https://doi.org/10.3389/fonc.2020.01222
[16]
Brower, J.V., Chen, S., Bassetti, M.F., Yu, M., Harari, P.M., Ritter, M.A., et al. (2016) Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. International Journal of Radiation Oncology, Biology, Physics, 96, 985-993.
https://doi.org/10.1016/j.ijrobp.2016.08.016
[17]
Ren, X., Wang, L., Han, C. and Ren, L. (2018) Retrospective Analysis of Safety Profile of High-Dose Concurrent Chemoradiotherapy for Patients with Oesophageal Squamous Cell Carcinoma. Radiotherapy and Oncology, 129, 293-299.
https://doi.org/10.1016/j.radonc.2018.09.006
[18]
You, J., Zhu, S., Li, J., Li, J., Shen, J., Zhao, Y., et al. (2023) High-Dose versus Standard-Dose Intensity-Modulated Radiotherapy with Concurrent Paclitaxel Plus Carboplatin for Patients with Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. International Journal of Radiation Oncology, Biology, Physics, 115, 1129-1137.
https://doi.org/10.1016/j.ijrobp.2022.11.006
[19]
Xu, Y., Dong, B., Zhu, W., Li, J., Huang, R., Sun, Z., et al. (2022) A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 28, 1792-1799.
https://doi.org/10.1158/1078-0432.CCR-21-3843
[20]
Hulshof, M.C.C.M., Geijsen, E.D., Rozema, T., Oppedijk, V., Buijsen, J., Neelis, K.J., et al. (2021) Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients with Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of Clinical Oncology, 39, 2816-2824. https://doi.org/10.1200/JCO.20.03697
[21]
Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J.M., Gavaghan, D.J. and McQuay, H.J. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12.
https://doi.org/10.1016/0197-2456(95)00134-4
[22]
Crehange, G., M’Vondo, C., Bertaut, A., Pereira, R., Rio, E., Peiffert, D., et al. (2021) Dose Escalated Chemoradiotherapy in Esophageal Cancer: Randomized Phase 2/3 CONCORDE Trial. Radiotherapy and Oncology, 161, S249-S250.
https://doi.org/10.1016/S0167-8140(21)06869-9
[23]
Ma, J., Wang, Z., Wang, C., Chen, E., Dong, Y., Song, Y., et al. (2017) Individualized Radiation Dose Escalation Based on the Decrease in Tumor FDG Uptake and Normal Tissue Constraints Improve Survival in Patients with Esophageal Carcinoma. Technology in Cancer Research & Treatment, 16, 75-80.
https://doi.org/10.1177/1533034615627583
[24]
Nayan, N., Bhattacharyya, M., Jagtap, V.K., Kalita, A.K., Sunku, R. and Roy, P.S. (2018) Standard-Dose versus High-Dose Radiotherapy with Concurrent Chemotherapy in Esophageal Cancer: A Prospective Randomized Study. South Asian Journal of Cancer, 7, 27-30. https://doi.org/10.4103/sajc.sajc_178_17
[25]
Zhu, W.-G., Zhou, K., Yu, C.-H., Han, J.-H., Li, T. and Chen, X.-F. (2012) Efficacy Analysis of Simplified Intensity-modulated Radiotherapy with High or Conventional Dose and Concurrent Chemotherapy for Patients with Neck and Upper Thoracic Esophageal Carcinoma. Asian Pacific Journal of Cancer Prevention, 13, 803-807. https://doi.org/10.7314/APJCP.2012.13.3.803
[26]
Trotti, A., Colevas, A.D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003) CTCAE v3.0: Development of a Comprehensive Grading System for the Adverse Effects of Cancer Treatment. Seminars in Radiation Oncology, 13, 176-181.
https://doi.org/10.1016/S1053-4296(03)00031-6
[27]
Zhang, J., Li, M., Zhang, K., Zheng, A., Li, G., Chen, S., et al. (2022) Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial. International Journal of Radiation Oncology, Biology, Physics, 114, S15.
https://doi.org/10.1016/j.ijrobp.2022.07.357
[28]
Zhu, H., Liu, Q., Xu, H., Mo, M., Wang, Z., Lu, K., et al. (2022) Dose Escalation Based on 18F-FDG PET/CT Response in Definitive Chemoradiotherapy of Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase III, Open-Label, Randomized, Controlled Trial (ESO-Shanghai 12). Radiation Oncology, 17, Article No. 134. https://doi.org/10.1186/s13014-022-02099-y
[29]
Bridges, S., Thomas, B., Radhakrishna, G., Hawkins, M., Holborow, A., Hurt, C., et al. (2022) SCOPE 2—Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: A Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response Using Positron Emission Tomography/Computed Tomography. Clinical Oncology, 34, e269-e80. https://doi.org/10.1016/j.clon.2022.03.019
[30]
Yu, W.-W., Zhu, Z.-F., Fu, X.-L., Zhao, K.-L., Mao, J.-F., Wu, K.-L., et al. (2014) Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in Esophageal Carcinoma: Early Results of a Phase II Study. Strahlentherapie und Onkologie, 190, 979-986. https://doi.org/10.1007/s00066-014-0636-y
[31]
Chen, Y., Zhu, H.-P., Wang, T., Sun, C.-J., Ge, X.-L., Min, L.-F., et al. (2017) What Is the Optimal Radiation Dose for Non-Operable Esophageal Cancer? Dissecting the Evidence in a Meta-Analysis. Oncotarget, 8, 89095-89107.
https://doi.org/10.18632/oncotarget.18760
[32]
Welsh, J.W., Seyedin, S.N., Allen, P.K., Hofstetter, W.L., Ajani, J.A., Chang, J.Y., et al. (2017) Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. Journal of Thoracic Oncology, 12, 375-382.
https://doi.org/10.1016/j.jtho.2016.10.013
[33]
Yu, W., Cai, X.-W., Liu, Q., Zhu, Z.-F., Feng, W., Zhang, Q., et al. (2015) Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose within the Primary Tumor Guided by 18FDG-PET/CT for Esophageal Cancer. Radiotherapy and Oncology, 114, 195-200. https://doi.org/10.1016/j.radonc.2014.12.007
[34]
Creemers, A., Ebbing, E.A., Pelgrim, T.C., Lagarde, S.M., van Etten-Jamaludin, F.S., van Berge Henegouwen, M.I., et al. (2018) A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Resectable Esophageal Adenocarcinomas. Scientific Reports, 8, Article No. 13281. https://doi.org/10.1038/s41598-018-31548-6
[35]
Conroy, T., Galais, M.-P., Raoul, J.L., Bouche, O., Sophie, G.B., Douillard, J.Y., et al. (2012) Phase III Randomized Trial of Definitive Chemoradiotherapy (CRT) with FOLFOX or Cisplatin and Fluorouracil in Esophageal Cancer (EC): Final Results of the PRODIGE 5/ACCORD 17 Trial. Journal of Clinical Oncology, 30, Article ID: LBA4003. https://doi.org/10.1200/jco.2012.30.18_suppl.lba4003
[36]
van Hagen, P., Hulshof, M.C., van Lanschot, J.J., Steyerberg, E.W., van Berge Henegouwen, M.I., Wijnhoven, B.P., et al. (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. The New England Journal of Medicine, 366, 2074-2084. https://doi.org/10.1056/NEJMoa1112088
[37]
Crehange, G., Bertaut, A., Bosset, J.F., Boustani, J., Rouffiac, M., Ghiringhelli, F., et al. (2017) Exclusive Chemoradiation with Carboplatin-Taxol vs Folfox-4 in Locally Advanced Esophageal Cancer. Radiotherapy and Oncology, 123, S671.
[38]
van Ruler, M.A.P., Peters, F.P., Slingerland, M., Fiocco, M., Grootenboers, D.A.R.H., Marijnen, C.A.M., et al. (2015) Clinical Outcomes of Definitive Chemoradiotherapy Using Carboplatin and Paclitaxel in Esophageal Cancer. Radiotherapy and Oncology, 115, S657-S658.
[39]
Chen, Y., Ye, J., Zhu, Z., et al. (2019) Comparing Paclitaxel plus Fluorouracil versus Cisplatin plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial. Journal of Clinical Oncology, 37, 1695-1703. https://doi.org/10.1200/JCO.18.02122
[40]
Liu, Y., Ren, Z., Yuan, L., et al. (2016) Paclitaxel plus Cisplatin vs. 5-Fluorouracil plus Cisplatin as First-Line Treatment for Patients with Advanced Squamous Cell Esophageal Cancer. American Journal of Cancer Research, 6, 2345-2350.
